Skip to content

Construction of Special Disease Cohort Database and Biological Sample Holographic Database of Severe Pneumonia

Construction of Special Disease Cohort Database and Biological Sample Holographic Database of Severe Pneumonia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04882436
Enrollment
1000
Registered
2021-05-12
Start date
2021-04-01
Completion date
2022-09-30
Last updated
2021-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Holographic Library of Biological Samples, Severe Pneumonia, Special Disease Cohort Database

Brief summary

The incidence rate and mortality of lung infection are high worldwide. It is a common and frequently occurring disease which seriously threatens human health. Severe pneumonia accounts for 18-36% of all pneumonia. Severe pneumonia has caused serious economic and medical burden. Therefore, it is urgent to carry out the real-world cohort study of severe pneumonia. Big data and sample library will provide useful clinical guidance and scientific research reserves for clinicians. Through further research, we can improve the treatment success rate and reduce the mortality. The purpose of this study is to provide reliable biological samples and related data information for the relevant basic and clinical trials in the field of severe pneumonia by carrying out the construction of special disease cohort database and biological sample holographic database, and to establish a long-term sharing platform for the transformation of research results into clinical practice, improve the prognosis of severe pneumonia,and provide the evidence for improving the diagnosis and treatment of severe pneumonia suitable for China's national conditions.

Interventions

None listed

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Recent cough, expectoration or aggravation of original respiratory diseases, with or without purulent sputum / chest pain / dyspnea / hemoptysis * Fever * Signs of pulmonary consolidation and / or moist rales * Peripheral blood leukocytes \>10×10\^9/L or less than 4×10\^9/L, with or without nucleus shifting to the left. * New patchy infiltration, consolidation of lobes / segments, ground glass opacity or interstitial changes, with or without pleural effusion on chest imagings * Positive etiological examination * Age \> 18 years old * Need mechanical ventilation; septic shock need vasoactive drug treatment. Meet one of them. * ① respiratory rate ≥ 30 beats / min; ② oxygenation index (PaO2 / FiO2) ≤ 250; ③ multilobar infiltration; ④ disturbance of consciousness / disorientation; ⑤ azotemia (BUN ≥ 20mg / dl); ⑥ cytopenia (WBC \< 4.0 × 109 / L); ⑦ thrombocytopenia (platelet \< 10.0 × 109 / L); Ⅷ low body temperature (T \< 36 ℃); Ⅸ hypotension, requiring strong fluid resuscitation. Meet the above three requirements at the same time.

Exclusion criteria

● Cannot understand and / or implement the investigation protocol.

Design outcomes

Primary

MeasureTime frameDescription
clinical outcome of patients with severe pneumoniaday 3, day 7, day 14, day 30, day 180.The pneumonia is cured or improved, or the treatment of pneumonia is invalid, or the patient is dead.

Countries

China

Contacts

Primary ContactJieming Qu, MD,PhD
jmqu0906@163.com+86-21-64370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026